# Safety and Efficacy Study of Botulinum Toxin Type A to Treat Lower Urinary Symptoms Due to Benign Prostatic Hyperplasia

> **NCT00284518** · PHASE2 · COMPLETED · sponsor: **Allergan** · enrollment: 380 (actual)

## Conditions studied

- Benign Prostatic Hyperplasia

## Interventions

- **BIOLOGICAL:** botulinum toxin Type A
- **DRUG:** normal saline

## Key facts

- **NCT ID:** NCT00284518
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** 2009-05
- **Final completion:** 2010-05
- **Target enrollment:** 380 (ACTUAL)
- **Last updated:** 2012-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00284518

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00284518, "Safety and Efficacy Study of Botulinum Toxin Type A to Treat Lower Urinary Symptoms Due to Benign Prostatic Hyperplasia". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00284518. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*